Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
What Studies Have NOT Demonstrated in Humans Despite community claims, no controlled human trial has demonstrated: A specific body fat percentage reduction attributable to LR3 IGF-1 cycling A specific lean mass gain figure for the standard 10-day-on / 4-week-off pattern Cardiovascular safety endpoints across repeated cycles Long-term cancer-incidence data for cycled LR3 IGF-1 use Epidemiological data on chronically elevated endogenous IGF-1 has raised theoretical cancer concerns (Yoshida & Delafontaine, 2020), and that concern is one reason community protocols favor short, spaced cycles rather than continuous use
Consult your healthcare provider : Discuss your reasons for discontinuation and whether it is truly necessary
High GHRH-R Selectivity No GHS-R1a Cross-Reactivity Modified GRF (1-29) demonstrates high selectivity for GHRHR, with minimal cross-reactivity to other pituitary hormone receptors including the growth hormone secretagogue receptor (GHS-R1a) that mediates the effects of ghrelin and GHRPs such as Ipamorelin
After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73)
Its not for those who havent tried lifestyle changes or who have certain health conditions
